Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The EU NIS 2 Directive Is Here. What Does It Mean For Medtech?

Executive Summary

The EU Network and Information Security (NIS) Directive 2 entered into force this year, replacing the original NIS Directive. Cybersecurity is at the heart of NIS 2, and some of the new provisions are particularly important for the medtech and health sector.

You may also be interested in...



EMA Begins Setting Up New Bodies To Tackle Medical Product Shortages

A new EU regulation has come into effect that gives the European Medicines Agency wider powers to monitor, prevent and manage shortages of drugs and medical devices in public health emergencies. A number of steering groups and other bodies and networks are being set up to put the new systems into action.

EU Orphan Drug Law Reform Will See Innovation Drop By 12%, Industry Warns

The European Commission’s proposals to overhaul the EU pharma legislation, which will see some orphan drug incentives cut, would cause a “significant dip in innovation,” according to number crunching from pharma industry association EFPIA.

Tackling AMR: OECD Says Greater Investment Needed In Later-Stage Drug R&D

Governments should increase financial resources for novel antimicrobial drug candidates in the later stages of development and tackle shortages of existing, underused antibiotics to combat antimicrobial resistance, says a new report from the OECD.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT147735

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel